Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.

Over the past two years, Eli Lilly has earned approval for such products as Alzheimer's disease (AD) treatment Kisunla, ulcerative colitis drug Omvoh, cancer medicine Jaypirca, and eczema therapy ...

Tirzepatide is offered by Eli Lilly in two weight loss products. Firstly, there is Mounjaro, which is approved for managing type 2 diabetes. Secondly, there is Zepbound, which is approved for ...

Besides its existing GLP-1 offerings, Eli Lilly may appeal to investors for its pill version of tirzepatide—likely on the horizon in 2026—as well as for its oncology products. Indeed ...

Given their strong track record and robust pipeline of potential new products, Lilly should be well positioned to navigate these challenges successfully. Eli Lilly's Q4 FY24 guidance revision ...

The maker of weight-loss drugs Mounjaro and Zepbound said sales of the drugs grew slower than expected in the fourth quarter, along with lower-than-expected inventory of the products. Eli Lilly ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...

In Eli Lilly's most recent quarter, which ended on Sept. 30, 2024, it grew its sales by 20% to $11.4 billion. It also had multiple products that generated over $1 billion in revenue, including its ...